Patients undergoing PCI for acute MI complicated by cardiogenic shock (AMICS) had worse outcomes—including more mortality and bleeding—when their hemodynamic support during that hospitalization was ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

DANVERS, Mass.--(BUSINESS WIRE)--To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support, Abiomed announces a ...

Please provide your email address to receive an email when new articles are posted on . In some analyses, percutaneous microaxial LVAD for cardiogenic shock was tied to worse outcomes vs. medical ...

Another observational study has questioned whether Impella ventricular assist pumps (Abiomed) should be used in patients with acute myocardial infarction (MI) complicated by cardiogenic shock (CS), at ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Abiomed announced a recall of its LVAD due to ...

The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area ≥1.5 m 2, who develop acute right heart failure or ...

For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...

Impella 2.5, the main product for Danvers, MA-based Abiomed Inc., has received FDA premarket approval (PMA) for use in elective and urgent high-risk percutaneous coronary intervention (PCI) procedures ...

In October 2019, the first U.S. patients were successfully treated by cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center. Since then, more than 120 ...